From Zn to Mn: the study of novel manganese-binding groups in the search for new drugs against tuberculosis. by Williams, Sarah L et al.
UC San Diego
UC San Diego Previously Published Works
Title
From Zn to Mn: the study of novel manganese-binding groups in the search for new 
drugs against tuberculosis.
Permalink
https://escholarship.org/uc/item/4dx035p9
Journal
Chemical biology & drug design, 77(2)
ISSN
1747-0277
Authors
Williams, Sarah L
de Oliveira, César Augusto F
Vazquez, H
et al.
Publication Date
2011-02-01
DOI
10.1111/j.1747-0285.2010.01060.x
 
Peer reviewed
eScholarship.org Powered by the California Digital Library
University of California
From Zn to Mn: The Study of Novel Manganese-
binding Groups in the Search for New Drugs
against Tuberculosis
Sarah L. Williams1,*, Ce´sar Augusto F. de
Oliveira1,2, H. Vazquez1 and J. Andrew
McCammon1,2,3,4
1Department of Chemistry & Biochemistry, University of California
San Diego, La Jolla, CA 92093-0365, USA
2Howard Hughes Medical Institute, University of California
San Diego, La Jolla, CA 92093-0365, USA
3Center for Theoretical Biological Physics, University of California
San Diego, La Jolla, CA 92093, USA
4Department of Pharmacology, University of California San Diego,
La Jolla, CA 92093-0365, USA
*Corresponding author: Sarah L. Williams,
swilliam@mccammon.ucsd.edu
In most eubacteria, apicomplexans, and most
plants, including the causal agents for diseases
such as malaria, leprosy, and tuberculosis, the
methylerythritol phosphate pathway is the route
for the biosynthesis of the C5 precursors to the
essential isoprenoid class of compounds. Owing
to their absence in humans, the enzymes of the
methylerythritol phosphate pathway have become
attractive targets for drug discovery. This work
investigates a new class of inhibitors against the
second enzyme of the pathway, 1-deoxy-D-xylulose
5-phosphate reductoisomerase. Inhibition of this
enzyme may involve the chelation of a crucial
active site Mn ion, and the metal-chelating moie-
ties studied here have previously been shown to
be successful in application to the zinc-dependent
metalloproteinases. Quantum mechanics and
docking calculations presented in this work sug-
gest the transferability of these metal-chelating
compounds to Mn-containing 1-deoxy-D-xylulose 5-
phosphate reductoisomerase enzyme, as a promis-
ing starting point to the development of potent
inhibitors.
Key words: drug design, drug discovery, molecular modeling,
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Tuberculosis (TB) is a serious infectious disease caused by the
Mycobacterium tuberculosis bacterium. It is a major cause of illness
and death, and owing to a rise in HIV cases, the neglect of TB
control programs, and an increase in drug resistance, the disease
has resurged in recent years in well-developed countries and has
exacerbated the TB problem in the lesser developed countries (1).
Therefore, there is an urgent need for the development of new
drugs and suitable therapeutic targets.
In most eubacteria, apicomplexans, and most plants, including the
causal agents for diseases such as malaria, leprosy, and tuberculo-
sis, the methylerythritol phosphate pathway (MEP, also known as
the DOXP or non-mevalonate pathway) is the route for the biosyn-
thesis of isopentenyl diphosphate and its isomer, dimethylallyl
diphosphate (DMAPP), the common C5 precursors to isoprenoids (2–
5). Isoprenoids comprise a large and diverse family of compounds
with numerous vital and diverse functions, with involvement in pro-
cesses such as respiration, electron transport, hormone-based sig-
naling, and membrane stability (6,7).
The MEP pathway comprises nine enzymes (8,9), all of which have
been identified as viable drug targets by genetic approaches (10,11)
and are of particular interest owing to their absence in humans,
who use the alternative mevalonate pathway (10,12). The 1-deoxy-
D-xylulose 5-phosphate reductoisomerase (DXR) enzyme is the most
studied of the pathway's enzymes to date. This enzyme is involved
in the second stage of the pathway, mediating the reversible
intramolecular rearrangement and NADPH-dependent reduction of
1-deoxy-D-xylulose 5-phosphate (DXP) to 2-C-methyl-D-erythritol
4-phosphate (MEP) in the presence of a divalent metal ion (for
which Mn2+ has shown to be the most effective (13)).
Drugs, such as fosmidomycin and its analogs, whose structure is
similar to the natural substrate have been developed and shown to
be efficacious against the Escherichia coli (14) and Plasmodium
falciparum (15,16) DXR enzymes. As with the natural substrate, the
inhibitors chelate the divalent metal ion present in the active site
of the enzyme. However, as observed with the majority of antibiot-
ics and chemotherapeutic agents, these inhibitors are ineffective in
vivo against the M. tuber strain of the enzyme (17). In the case of
fosmidomycin, the lack of potency has been attributed to the com-
plex and hydrophobic nature of the mycobacterial cell wall and the
absence of a cAMP-dependent glycerol-3-phosphate transporter pre-
venting the uptake of such a small and highly charged molecule
(18). Even in the absence of these resistance issues, such as in
the treatment against the P. falciparum pathogen, the late
recrudescence observed in clinical trials precludes the drug as a
monotherapy, with efficacious treatment requiring it to be
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administered with clindamycin (15,16). Clinical studies have also
shown that repeated and comparably high doses of the drug are
required to achieve acceptable cure rates (15,16). Furthermore,
although the hydroxamate moiety of fosmidomycin exhibits attractive
metal-chelating properties, these compounds are associated with
low availability, poor in vivo stability, and undesirable side-effects,
making them often undesirable in the manufacture of drugs (19).
In this study, we propose an alternative metal-chelating group to
hydoxamate, as a starting point for the development of a new class
of inhibitors against the DXR enzyme. Cohen et al. have identified
and synthesized a group of compounds, which are indicated to be
successful alternatives to hydroxamate in the chelation of Zn2+, in
the Zn-dependent matrix metalloproteinases (MMP) (20). The struc-
tures of the ligands featured in this study comprise hydroxypyridi-
nones, hydroxpyridinethiones, pyrones, and thiopyrones (Figure 1).
The study by Cohen et al. found these ligands to share similarities
to the hydroxamate moiety in terms of their bidentate-chelate for-
mation properties, with improved hydrolytic stability and biologic
tolerance, and proposed an increase in affinity toward Zn.
In this work, the computational techniques of quantum mechanics
(QM) and QM-polarized docking calculations were used to study the
potential of these metal-binding groups (MBGs) as potential Mn-
binding moieties, as part of a search for a new class of inhibitors
against the 1-deoxy-D-xylulose 5-phosphate reductoisomerase
(MtDXR) enzyme. This study provides promising results, indicating
these compounds to possess similar or improved binding affinities
against the MtDXR enzyme, when compared to the reference
hydroxamate-based compound, acetohydroxamic acid (AHA), there-
fore suggesting them to be good candidates for further develop-
ment in an effort to produce potent inhibitors.
Computational details
Quantum mechanics calculations
Modeling ligand binding can be problematic using conventional
methods, with issues such as polarization and charge transfer being
inadequately accounted for in the usual forcefields. This can be a
hurdle in the design of novel and potent inhibitors and is exacer-
bated with the presence of metal ions in the active site. In an
attempt to determine whether the 12 proposed chelating moieties
(Figure 1), taken from the study by Cohen et al., would form che-
lates with a Mn2+ ion, QM calculations were used to predict the
binding affinity.
For this purpose, the affinity between the Mn2+ ion and the ligand
was measured in the absence of the protein environment, using a
Mn2+-containing scaffold molecule, based on a Mn+2 complex syn-
thesized by Nabika et al. (21) (Figure 2), [Mn(II) tris(3.5-diisopropyl-
1-pyrazolyl) methane]. This scaffold and the 12 compounds shown
in Figure 1 were constructed using a drawing program available in
Maestro. The ligand preparation wizard was used to add hydrogen
atoms to each of the 12 compounds, with the hydroxyl groups
assumed to be deprotonated at the protein active site at a pH of 7.
Prior to calculations, each of the compounds was positioned at the
same distance from the Mn2+ ion, as observed in the crystal struc-
ture of the MtDXR enzyme when bound to fosmidomycin (PDB ID:
2JCZ).
For the geometry optimization, a BL3YP level of theory was applied,
and for the energy calculations, LMP2 ⁄ LACVP*+ level of theory was
used, with the energies being counterpoise-corrected.
Figure 1: Structures of the metal-chelating groups (acetohydroxamic acid and metal-binding groups 1–11) examined in this study.
Figure 2: Model system used in the quantum mechanics study
to calculate the binding energy of each metal-binding groups (MBGs
1–11, see Figure 1) to the model compound.
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Docking calculations
Generation of different active site
conformations of MtDXR
Each of the 12 compounds shown in Figure 1 was computationally
docked into the active site of monomer A of the MtDXR crystal
structure (Table 2, PDB ID: 2JCZ), and three other conformations
(labeled A-C in Table 2) selected from a prior study which examined
the dynamics of the enzyme using an enhanced sampling MD tech-
nique (22). These three conformations were identified by clustering
analysis as being the dominant conformations sampled throughout
the simulations, together accounting for almost 70% of the total
number of conformations sampled (see reference (22) for details).
The active site of the crystal structure that is bound with the fosmi-
domycin inhibitor (PDB ID: 2JCZ, monomer A) is observed to be the
most closed of the four conformations shown here, with an impor-
tant catalytic loop overhanging and enclosing the binding site to
the greatest extent. Structures A and B represent the monomer in
conformations intermediate between the closed crystal structure
and the most open form observed in Structure C (see Table 2),
where the catalytic loop has moved away, exposing the active site.
QM-polarized docking calculations
In this study, the QM-polarized ligand-docking protocol of the Schrç-
dinger suite (23) was utilized to dock the 12 MBGs into the active
site of the four conformations of MtDXR. This protocol improves
docking accuracy over the non-QM docking, through the use of QM
calculations (QSite package in Maestro) to determine the partial
charges on the ligand atoms in the field of the receptor molecule,
thus accounting for charge polarization. The purpose of this docking
study was to determine the orientation of the ligands within the
active site and predict any potential interactions with neighboring
residues. The compound labeled 'AHA' (Figure 1) is the hydroxamate
template ligand and is used as a reference compound for the dock-
ing of the 11 alternative metal-chelating groups studied here. The
metal-chelating properties of the hydroxamate group are well estab-
lished, and crystal structures observe the MtDXR enzyme inhibitor,
fosmidomycin, to form bidentate chelates between the inhibitor
hydroxamate moiety and the active site metal ion (24–26).
Prior to the calculation, each of the protein and ligand structures
was prepared, with hydrogens added according to the expected pro-
tonation at pH 7, using the protein preparation and ligand prepara-
tion wizards available within Maestro. A grid of an appropriate
size, which fully incorporated the active site of the enzyme, was
applied as the target area for the docking calculations.
The QM-polarized docking protocol initially docked each of the
ligands using Glide before deriving the charges of the five top
ligand poses in the field of the receptor, using QM calculations
(QSite). In the final stage of the protocol, these poses are redocked
into the active site of the receptor with the new charges, and the
top 10 scoring poses were recorded.
Results
One of the most frequently applied strategies in the development
of metalloproteinase inhibitors consists in the design of molecules
that contain a metal-chelating group (MBG) and backbone frag-
ments (27). The backbones are drug-like structures that interact
with active site binding pockets through non-covalent interactions,
conferring selectivity toward a specific metalloprotein receptor. In
recent years, Cohen and collaborators have expanded the library of
MBGs for zinc-containing enzymes by introducing a new bioinorgan-
ic approach to design new matrix metalloproteinase inhibitors
(20,28–35). The main idea behind the bioinorganic approach is to
use small molecule complexes to model the active site of metal-
loenzymes. The complex [(TpPh,Me)Zn(OH)] (TpPh,Me = hydrotris(3,5-
phenylmethylpyrazolyl)borate) has been successfully applied to
model the active site of zinc(II)-dependent MMP (20,31). The
hypothesis is that as the three pyrazole rings mimic the catalytic
histidines bound to the zinc in the MMP active site, the character-
ized complexes formed between the MBG and [(TpPh,Me)Zn(OH)]
reflect the binding mode of the chelating group. This assumption
has been supported by comparing the complex of [(TpPh,Me)Zn(AHA)],
where AHA stands for acetohydroxamic acid, with the available
crystal structures of the complexes formed between MMPs and
hydroxamate-based inhibitors (31). In addition, by using this
approach, the Cohen group was able to propose new classes of
matrix metalloproteinase inhibitors exhibiting improved potency and
novel selectivity relative to similar hydroxamic-based inhibitors
against MMPs and anthax lethal factor (35–37).
Although several zinc-binding groups have been proposed in the lit-
erature, hydroxamic acid functional groups are still by far the most
used MBG in MMP inhibitors (27). Similarly, fosmidomycin and its
analogs also display the hydroxamate moiety in their structure.
However, as aforementioned, hydroxamate-based MMP inhibitors
are often associated with poor pharmacokinetics, poor oral bioavail-
ability and toxicity (38–40). Monoanionic bidentate zinc-chelators
such as pyrones, hydroxypyridinones, and their thione analogs
(Figure 1) were the first heterocycles reported in the literature that
showed significantly improved potency against MMPs when com-
pared to acetohydroxamic acid (32,41). These compounds have been
considered as very promising alternatives to hydroxamic acid owing
to their low toxicity and relatively high potency against MMPs in
cell culture (41).
Table 1: Relative Mnaffinity (Eqn 1) of proposed metal-binding
groups
Metal-binding groups DMnaffinity (fold)
1 1.0
2 0.9
3 1.1
4 0.9
5 0.9
6 0.9
7 0.9
8 0.9
9 1.1
10 0.9
11 0.9
Investigation into New Inhibitors against M. tuber
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Although some hydroxypyrone and hydroxypyridinone MBGs can mod-
ulate selective inhibition of MMPs when linked to biphenyl backbone
fragments (42), it is usually assumed that the chelating group itself
does not contribute significantly to selectivity. Because the main func-
tion of the MBG in the inhibitor molecules is to co-ordinate the cata-
lytic metal, it has been proposed that the chelating group mainly
contributes to the binding affinity of the inhibitor–metalloprotein com-
plex. The lack of selectivity of acetohydroxamic acid for metal ions,
such as Zn2+ and Mn2+, is also shown by the presence of a
hydroxamic acid functional group in both DXR and MMP inhibitors.
To our knowledge, neither experimental nor theoretical work has
investigated the use of pyrone-based molecules as chelating groups
for enzymes besides zinc-dependent metalloproteins. In this work,
we estimate the affinity of these newly identified metal-chelating
groups to Mn+2 through the use of QM calculations to evaluate
their binding energies according to the scheme showed in Figure 2.
Inspired by the bioinorganic approach of Puerta et al. (34), we use
the Mn2+ complex with tris(3,5-diisopropyl-1-pyrazolyl)methane
ligand as our model compound to mimic the active site of MtDXR
(21). To reduce computational cost, all isopropyl groups were substi-
tuted by hydrogen atoms. The relative affinity to Mn+2 (DMnaffinity)
of each compound was defined according to eqn 1, where the
energy difference between the bound and unbound states was cal-
culated for each MBG, relative to AHA.
DMnaffinity ¼ DEMBGDEAHA ð1Þ
where DE is defined by,
DEX ¼ E ComplexXModel Compound  EX þ EModel Compound
 
ð2Þ
where X corresponds to a MBG structure in Figure 1.
Table 1 shows the binding affinity of each MBG, relative to AHA,
obtained from the QM calculations made on the model system dis-
played in Figure 2. These results indicate that MBGs 1-11 have very
similar affinity to Mn2+ when compared to AHA. Our QM calcula-
tions suggest that substitution of the hydroxamate moiety by any of
the MBGs 1–11 can be well tolerated without compromising the
inhibitor potency against MtDXR. To further explore the use of
MBGs 1–11 in the design of MtDXR inhibitors, we carried out dock-
ing studies to evaluate their binding mode, metal chelation, and
interactions with the MtDXR active site resides.
Each of the ligands numbered 1–11 in Figure 1 and the reference
compound, AHA, were docked into the four varied active site con-
formations (shown in Table 2) of monomer A of the MtDXR
enzyme, as described in the Methods section. The docking calcu-
lations showed that the majority of the compounds achieve a
pose whereby the O, O (ligands 1–6) or S, O (ligands 7–11)
donor atoms of the ligands form a bidentate chelate with the Mn
ion, in a very similar orientation to what is observed with the
hydroxamate moiety of the fosmidomycin inhibitor (and AHA refer-
ence compound) in the crystal structure. For a few of the ligands,
a suitable docking pose was not achieved in all of the active site
conformations, and this has been denoted by the absence of an
entry in Table 2.
Table 2: Relative binding affinity (DDGXP = docking score (Glide XP in kcal ⁄mol) of acetohydroxamic acid (AHA) in the crystal structure –
ligand docking score of AHA and compounds 1–11 into the crystal structure (monomer A of PDB ID: 2JCZ) and three predominant conforma-
tions sampled in a prior dynamics study (Conformations A–C). In a few cases, the ligands do not achieve acceptable docking poses where the
ligand forms the bidentate chelate, and as a result, no docking score has been recorded (denoted as '–')
Ligand Crystal structure Conformation A Conformation B Conformation C
AHA (ref) 0 )1.21 )0.27 0.83
1 1.32 )0.17 0.34 1.18
2 1.77 0.89 0.80 0.43
3 0.89 – )0.29 0.42
4 )0.29 )1.61 1.13 0.57
5 0.04 )1.44 )0.38 0.47
6 )0.44 )1.85 )0.60 )1.17
7 1.27 )0.52 )0.09 )0.97
8 0.95 0.82 0.53 0.13
9 – 0.96 0.67 0.42
10 0.54 )0.80 – 0.42
11 1.82 )0.15 )0.89 0.58
Williams et al.
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On docking each ligand into the four different MtDXR conforma-
tions, variation is observed in the docking scores and poses owing
to differences in active site volume of the various conformations
and the orientations of residue side chains in the vicinity of the
ligand. Generally, for ligands possessing bulky methyl groups, the
space restrictions presented by some of the conformations repre-
sented in this study cause them to achieve lower docking scores
than the non-methyl-containing ligands. This difference is most
apparent when comparing the docking scores of methyl-containing
ligands 2, 3, 8, 9, and 11, when docked into the crystal structure,
which has the most limited space within the active site, and Con-
formation C, which has the most available space of the four active
site conformations. The steric constraints imposed by the more
closed active sites recognize orientations of the ligand around the
metal ion, which possess less favorable interactions with the resi-
dues of the active site. An example is shown in Figure 3, where
ligand 2 flips orientation from its observed pose in the crystal struc-
ture active site conformation to that observed in Conformation C,
where there is now available space to allow the methyl group to
be positioned in a more hydrophobic neighborhood.
Of the 11 metal-chelating groups tested here, the non-methyl-con-
taining ligands tend to observe improved binding affinity in the
active site. Their best scores are observed in Conformation A,
where the active site is less restricted compared with the crystal
structure, but is still in a closed-type conformation, with the close
packing of the active site residues providing a good environment
for favorable interactions to exist. The consistently top ranked
binding score of ligand 6 across the four MtDXR conformations
indicates that an amide group at a position adjacent to the metal-
chelating carboxylate group on the ring may provide a favorable
contribution to the binding affinity.
All docked poses of the non-methyl-containing ligands exhibit the
catalytically important Trp loop residue to be in close proximity and
stacked over the ring of the ligand, providing the possibility for
p–p interactions to occur. The docking poses of these ligands vary
significantly, and of all the conformations, their least favorable
docking scores are achieved with Conformation C. The reason for
such differences in docking pose is illustrated in Figure 4, where
the side chains of the hydrophobic Trp203 loop residue and Met205
A B
Figure 3: Docking pose of ligand 2 in the active site of (A) the closed crystal structure and (B) the more open Structure C. Residues
shown as surface representation highlight the hydrophobic (blue) and polar (red) residues within 5  of ligand 6.
A B
Figure 4: Docking orientations of (A) ligand 4 and (B) ligand 6 in Conformations A (yellow) and B (tan). Residue side chains of active site
A are highlighted in ochra and those of active site B in green. The Mn2+ ion is shown as a green sphere, and the ligand poses are labeled A
and B to indicate the pose observed active sites A and B, respectively.
Investigation into New Inhibitors against M. tuber
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are shown to impinge on the docking space of the active site in
conformation B, sterically hindering the docking pose observed in
the active sites of the crystal structure and Conformations A and C.
This disrupts the favorable residue packing and opportunity for the
p–p stacking between the ligand and Trp residue.
In the case of Conformation C, the docking scores of the non-
methyl-containing ligands decrease slightly compared with Confor-
mation A owing to the active site being significantly more open,
with less opportunity for the ligand to interact with the more dis-
tant active site residues.
In summary, the docking calculations reveal the 11 zinc-binding moi-
eties to interact with the Mn ion to form a bidentate chelate, with
a similar or improved binding affinity compared with the hydroxa-
mate reference compound. The results suggest the ligands without
methyl substituents and possessing a polar group (e.g. amide) at a
position adjacent to the metal-chelating moiety on the ring would
provide improved interactions with the protein. In addition, the QM
calculations showed that the binding energies between the Mn ion
and compounds 1–11 are very similar to the one obtained for the
AHA reference compound.
Therefore, from the computational studies performed here, the com-
pounds are indicated to be promising candidates for experimental
testing as viable alternatives to the hydroxamate group for a new
class of inhibitors against the DXR enzyme in M. tuberculosis.
Conclusions
The results of this study suggest a series of MBGs as promising
candidates for the development of novel and potent inhibitors
against the crucial MtDXR enzyme in M. tuberculosis. These
pyrone-based structures, originally developed by the Cohen group
as metal-chelating groups for the Zn-dependent metalloproteinases,
are indicated by computational QM and docking studies, to be
transferable to the Mn-containing MtDXR enzyme.
Quantum mechanics calculations demonstrated the binding affinity
of each of the MBGs to Mn2+, as part of a scaffold structure, to be
comparable to the reference AHA compound, which is known to
chelate both Mn and Zn ions. QM-polarized docking calculations
revealed the MBGs to form bidentate chelates with the Mn ion, as
observed with fosmidomycin in the crystal structure, with similar or
improved binding affinity to the reference AHA compound. In addi-
tion to the crystal structure, this docking was performed using three
dominant protein conformations, as identified by MD simulations,
removing the bias generated by the fosmidomycin-preformed active
site conformation of the crystal structure, and provides increased
knowledge of favorable ⁄ unfavorable structural aspects of these
MBGs, which may be useful in the further development of these
compounds into specific and potent inhibitors of MtDXR.
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